Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
Phase 1
Completed
- Conditions
- Relapsed Multiple Myeloma
- Interventions
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 84
- Registration Number
- NCT00603447
- Locations
- 🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
Phase 3
Completed
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 34
- Registration Number
- NCT00603642
Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy
Phase 2
Terminated
- Conditions
- Hepatic Encephalopathy
- Interventions
- Drug: placebo solution (10% dextrose)Drug: sodium phenylacetate and sodium benzoate injection 10% / 10%
- First Posted Date
- 2008-01-18
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1
- Registration Number
- NCT00597909
- Locations
- 🇺🇸
Permian Research Foundation, Odessa, Texas, United States
🇺🇸UCSF-Fresno University, Fresno, California, United States
🇺🇸Loma Linda University Medical Center, Loma Linda, California, United States
Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma
Phase 2
Completed
- Conditions
- Gastrointestinal Cancer
- Interventions
- First Posted Date
- 2007-12-31
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 171
- Registration Number
- NCT00583674
Effect of Panitumumab on the Pharmacokinetics of Irinotecan
Phase 1
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2016-04-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 28
- Registration Number
- NCT00563316
- Locations
- 🇨🇦
Research Site, Toronto, Ontario, Canada
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
Phase 1
Completed
- Conditions
- LymphomaProstate CancerSarcomaUnspecified Adult Solid Tumor, Protocol SpecificSmall Intestine Cancer
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 64
- Registration Number
- NCT00562380
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- Drug: PlaceboBiological: DenosumabOther: Standard of CareDrug: Non-steroidal aromatase inhibitor therapy
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 3420
- Registration Number
- NCT00556374
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 14
- Registration Number
- NCT00551200
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Phase 2
Completed
- Conditions
- CancerHead and Neck CancerOncologySquamous Cell Carcinoma
- Interventions
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 152
- Registration Number
- NCT00547157
A Phase II Study of CCX282-B in Patients With Celiac Disease
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 90
- Registration Number
- NCT00540657
- Locations
- 🇫🇮
Finn-Medi Research Ltd, Outpatient Clinic, Tampere, Finland
© Copyright 2025. All Rights Reserved by MedPath